SCHEMBL25207807

SCHEMBL25207807

Oc1ccccc1-c1cc2c(ccn2C2CNC2)nn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PBRM1 Q86U86 15/20 0.41
▸ SMARCA2 P51531 14/20 0.41
▸ SMARCA4 P51532 14/20 0.41
▸ NR1I2 O75469 10/20 0.39
▸ BRD4 O60885 1/20 0.39
▸ NR1H2 P55055 4/20 0.36
▸ NR1H3 Q13133 3/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ ALOX15 P16050 1/20 0.35
▸ ALOX12 P18054 1/20 0.35
▸ NFKB1 P19838 1/20 0.35
▸ NFKB2 Q00653 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ RELA Q04206 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ IKBKB O14920 2/20 0.34
▸ CHUK O15111 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26801817 0.88 PBRM1 (0.42) PBRM1SMARCA2SMARCA4NR1I2BRD4
SCHEMBL30658034 0.88 PBRM1 (0.42) PBRM1SMARCA2SMARCA4NR1I2BRD4
SCHEMBL26157043 0.84 PBRM1 (0.38) PBRM1SMARCA2SMARCA4NR1I2BRD4
SCHEMBL26157041 0.79 PBRM1 (0.45) PBRM1SMARCA2SMARCA4NR1I2BRD4
SCHEMBL26654108 0.75 SMARCA2 (0.52) PBRM1SMARCA2SMARCA4BRD4
SCHEMBL30658054 0.75 SMARCA2 (0.52) PBRM1SMARCA2SMARCA4BRD4
SCHEMBL26654055 0.74 PBRM1 (0.37) PBRM1SMARCA2SMARCA4NR1I2BRD4
SCHEMBL26653822 0.72 PDE10A (0.42) PBRM1SMARCA2SMARCA4NR1I2BRD4
SCHEMBL25194756 0.72 PBRM1 (0.46) PBRM1SMARCA2SMARCA4NR1I2BRD4
SCHEMBL24461554 0.72 PBRM1 (0.39) PBRM1SMARCA2SMARCA4NR1I2BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250302832-A1 PYRAZINE DERIVATIVES AND USES THEREOF FOGHORN THERAPEUTICS INC (US) 2025-10-02 — — US disclosed
EP-4522279-A1 PYRAZINE DERIVATIVES AND USES THEREOF Foghorn Therapeutics Inc. (US) 2025-03-19 — — EP disclosed
WO-2023220134-A1 PYRAZINE DERIVATIVES AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2023-11-16 — — WO disclosed
WO-2023220134-A1 PYRAZINE DERIVATIVES AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2023-11-16 — — WO disclosed
WO-2023093728-A1 BRM SELECTIVE DEGRADATION AGENT COMPOUND AND USE THEREOF 江苏先声药业有限公司 2023-06-01 — — WO disclosed
WO-2023093728-A1 BRM SELECTIVE DEGRADATION AGENT COMPOUND AND USE THEREOF 江苏先声药业有限公司 2023-06-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250302832-A1 PYRAZINE DERIVATIVES AND USES THEREOF BRCA1, VHL, SF3B5 PBRM1 7/4885SMARCA2 77/4885SMARCA4 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback